Literature DB >> 18991521

Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study.

Rémy Gauzit1, Yves Péan, Xavier Barth, Frédéric Mistretta, Olivier Lalaude.   

Abstract

BACKGROUND: Despite improvements in treatment, secondary peritonitis still is associated with high morbidity and mortality rates. Better knowledge of real-life clinical practice might improve management.
METHODS: Prospective, observational study (January-June 2005) of 841 patients with non-postoperative secondary peritonitis.
RESULTS: Peritonitis originated in the colon (32% of patients), appendix (31%), stomach/duodenum (18%), small bowel (13%), or biliary tract (6%). Most patients (78%) presented with generalized peritonitis and 26% with severe peritonitis (Simplified Acute Physiology Score [SAPS] II score>38). Among the 841 patients, 27.3% underwent laparoscopy alone; 11% underwent repeat surgery, percutaneous drainage, or both. A SAPS II score>38 and the presence of Enterococcus spp. were predictive of abdominal and non-surgical infections (odds ratio [OR]=1.84; p=0.013 and OR=2.93; p<0.0001, respectively). A SAPS II score>38 also was predictive of death (OR=10.5; p<0.0001). The overall mortality rate was high (15%). Patients receiving inappropriate initial antimicrobial therapy had significantly higher morbidity and mortality rates than patients receiving appropriate therapy (44 vs. 30%; p=0.004 and 23% vs. 14%; p=0.015, respectively). The SAPS II score and rates of severe peritonitis, morbidity, and mortality were significantly lower in patients with appendiceal peritonitis.
CONCLUSIONS: Patients with non-postoperative peritonitis should be considered high risk and should receive appropriate initial therapy. The presence of Enterococcus spp. in peritoneal cultures significantly increased morbidity but not the mortality rate. Appendiceal peritonitis that was less severe and had a better prognosis than peritonitis originating in other sites should be considered a special case in future studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18991521     DOI: 10.1089/sur.2007.092

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  20 in total

1.  Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis.

Authors:  Emilia Cercenado; Luis Torroba; Rafael Cantón; Luis Martínez-Martínez; Fernando Chaves; Jose Angel García-Rodríguez; Carmen Lopez-Garcia; Lorenzo Aguilar; César García-Rey; Nuria García-Escribano; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

Review 2.  Secondary peritonitis: principles of diagnosis and intervention.

Authors:  James T Ross; Michael A Matthay; Hobart W Harris
Journal:  BMJ       Date:  2018-06-18

3.  Preoperative prognostic factors for severe diffuse secondary peritonitis: a retrospective study.

Authors:  Matti Tolonen; Ville Sallinen; Panu Mentula; Ari Leppäniemi
Journal:  Langenbecks Arch Surg       Date:  2016-05-30       Impact factor: 3.445

4.  T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis.

Authors:  R V Anantha; D M Mazzuca; S X Xu; S A Porcelli; D D Fraser; C M Martin; I Welch; T Mele; S M M Haeryfar; J K McCormick
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

5.  Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study.

Authors:  M Guilbart; E Zogheib; A Ntouba; L Rebibo; J M Régimbeau; Y Mahjoub; H Dupont
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

6.  Essentials for selecting antimicrobial therapy for intra-abdominal infections.

Authors:  Stijn Blot; Jan J De Waele; Dirk Vogelaers
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

7.  Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Authors:  Joseph Solomkin; Ellie Hershberger; Benjamin Miller; Myra Popejoy; Ian Friedland; Judith Steenbergen; Minjung Yoon; Sylva Collins; Guojun Yuan; Philip S Barie; Christian Eckmann
Journal:  Clin Infect Dis       Date:  2015-02-10       Impact factor: 9.079

Review 8.  How to treat infections in a surgical intensive care unit.

Authors:  Jan De Waele; Liesbet De Bus
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

9.  Which cause of diffuse peritonitis is the deadliest in the tropics? A retrospective analysis of 305 cases from the South-West Region of Cameroon.

Authors:  Alain Chichom-Mefire; Tabe Alain Fon; Marcelin Ngowe-Ngowe
Journal:  World J Emerg Surg       Date:  2016-04-11       Impact factor: 5.469

10.  Impact of ventilator-associated pneumonia on mortality and epidemiological features of patients with secondary peritonitis.

Authors:  María Heredia-Rodríguez; María Teresa Peláez; Inmaculada Fierro; Esther Gómez-Sánchez; Estefanía Gómez-Pesquera; Mario Lorenzo; F Javier Álvarez-González; Juan Bustamante-Munguira; José María Eiros; Jesús F Bermejo-Martin; José I Gómez-Herreras; Eduardo Tamayo
Journal:  Ann Intensive Care       Date:  2016-04-18       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.